In patients with urothelial cancer, genetic variations linked to response to...
A gene signature comprising four different single-nucleotide polymorphisms associated with response to platinum-based therapy in patients with urothelial carcinoma has been identified by Irish and U.S....
View ArticleIntermittent androgen suppression techniques yield similar results
Intermittent androgen suppression is as effective as continuous androgen deprivation, according to a non-inferiority study of men with a rising PSA following definitive primary therapy for prostate...
View ArticleProstate cancer progression slowed by adding 5-alpha-reductase inhibitor to...
The 5-alpha-reductase inhibitor dutasteride (Avodart), when added to an active surveillance strategy, slows progression of prostate cancer in men with localized disease and decreases patient...
View ArticleImaging in prostate cancer patients often used inappropriately
A substantial proportion of patients over age 65 years with newly diagnosed prostate cancer are not being treated according to existing guidelines for imaging in this setting.read more
View ArticleImaging in prostate cancer patients often used inappropriately
A substantial proportion of patients over age 65 years with newly diagnosed prostate cancer are not being treated according to existing guidelines for imaging in this setting.read more
View ArticleInvestigational treatment improves survival in metastatic prostate cancer
In men with castration-resistant prostate cancer and symptomatic bone metastases, the investigational radiopharmaceutical radium-223 (Alpharadin) improved overall survival by 30% and time to first...
View ArticleInvestigational advanced prostate cancer treatment extends overall survival
The investigational oral androgen receptor signaling inhibitor MDV3100 significantly extended survival by about 5 months versus placebo in men with metastatic castration-resistant prostate cancer...
View ArticleNeoadjuvant immunotherapy safe in advanced prostate cancer
The autologous cellular immunotherapy sipuleucel-T (Provenge) can be safely given prior to radical prostatectomy, and in the neoadjuvant setting, the vaccine exerts a favorable effect on immune cells...
View ArticleResponders to renal cell carcinoma agent show longer survival rates
Responders to the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Sutent) have significantly longer progression-free survival and overall survival than non-responders, according to an...
View ArticleAndrogen blockade can be cut from 36 to 18 months
Patients with high-risk prostate cancer who undergo 18 months of androgen blockade live as long as those who have 36 months of treatment, according to results of a recent phase III study.read more
View ArticleAnticoagulant use predicts survival in metastatic PCa
Anticoagulation while on docetaxel (Taxotere) chemotherapy appears to be an independent predictor of survival in men with metastatic castration-resistant prostate cancer (mCRPC).read more
View ArticleData confirm value of 10- to 12-core prostate biopsy
Practice appears to increase detection of prostate cancer, study showsread more
View Article5-ARI does not affect prostate cancer mortality
Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention...
View ArticleAnticoagulant use predicts survival in metastatic prostate cancer
Anticoagulation while on docetaxel (Taxotere) chemotherapy is an independent predictor of survival in men with metastatic castration-resistant prostate cancer (mCRPC).read more
View Article5-ARI does not affect prostate cancer mortality
Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention...
View ArticleSemi-annual PSA may be safe for men on surveillance
No difference in progression seen for assessments at 3- vs. 6-month intervalsread more
View ArticleIn patients with urothelial cancer, genetic variations linked to response to...
A gene signature comprising four different single-nucleotide polymorphisms associated with response to platinum-based therapy in patients with urothelial carcinoma has been identified by Irish and U.S....
View ArticleIntermittent androgen suppression techniques yield similar results
Intermittent androgen suppression is as effective as continuous androgen deprivation, according to a non-inferiority study of men with a rising PSA following definitive primary therapy for prostate...
View ArticleProstate cancer progression slowed by adding 5-alpha-reductase inhibitor to...
The 5-alpha-reductase inhibitor dutasteride (Avodart), when added to an active surveillance strategy, slows progression of prostate cancer in men with localized disease and decreases patient anxiety.
View ArticleImaging in prostate cancer patients often used inappropriately
A substantial proportion of patients over age 65 years with newly diagnosed prostate cancer are not being treated according to existing guidelines for imaging in this setting.
View Article
